Gaboxadol: Difference between revisions

(4 intermediate revisions by 3 users not shown)

Line 2:

'''''~~Gaboxadol~~''''' is a [[depressant]] substance of the [[~~isoxazole~~]] class that produces [[sedative]], [[anxiolytic]], [[hypnotic]] and distinct [[hallucinogenic]] effects. It is chemically related to [[muscimol]], which is the primary alkaloid responsible for the [[psychoactive]] effects of [[amanita muscaria]]. It has been specifically developed alongside hundreds of other analogs to display more pronounced and selective therapeutic effects as well as a higher bioavailability than its parent compound muscimol.{{citation needed}}

'''Gaboxadol''' (also knows as '''THIP''', '''OV101''' and '''LU-2-030''') is a [[depressant]] substance of the [[chemical class::3-hydroxyisoxazole]] class that produces [[sedative]], [[anxiolytic]], [[hypnotic]] and distinct [[hallucinogenic]] effects. It is chemically related to [[muscimol]], which is the primary alkaloid responsible for the [[psychoactive]] effects of [[amanita muscaria]]. It has been specifically developed alongside hundreds of other analogs to display more pronounced and selective therapeutic effects as well as a higher bioavailability than its parent compound muscimol.{{citation needed}}

It was first synthesized in 1977 by the Danish chemist Povl Krogsgaard-Larsen. Since then it was subject to numerous medical evaluations for potential applications as an anxiolytic and hypnotic as well as treating conditions such as Alzheimer's disease among others. It's latest attempt at clinical trials was for the treatment of insomnia, although the trials have been cancelled.<ref>http://harpers.org/archive/2013/08/gaboxadol/</ref><ref>US Patent 4278676 - Heterocyclic compounds</ref>

According to its pharmacological action, it is among a few hypnotic substances that do not negatively alter or suppress sleep and sleep architecture. It increases stage 4 deep sleep<ref>{{cite journal | vauthors = Vashchinkina E, Panhelainen A, Vekovischeva OY, Aitta-aho T, Ebert B, Ator NA, Korpi ER | title = GABA site agonist gaboxadol induces addiction-predicting persistent changes in ventral tegmental area dopamine neurons but is not rewarding in mice or baboons | journal = The Journal of Neuroscience | volume = 32 | issue = 15 | pages = 5310–20 | date = April 2012 | pmid = 22496576 | doi = 10.1523/JNEUROSCI.4697-11.2012 | pmc = 6622081 | doi-access = free }}</ref> and simultaneously does not inhibit REM sleep,{{citation needed}} this is a trait currently unique to Gaboxadol.

According to its pharmacological action, it is among a few hypnotic substances that do not negatively alter or suppress sleep and sleep architecture. It increases stage 4 deep sleep<ref>{{cite journal | vauthors = Vashchinkina E, Panhelainen A, Vekovischeva OY, Aitta-aho T, Ebert B, Ator NA, Korpi ER | title = GABA site agonist gaboxadol induces addiction-predicting persistent changes in ventral tegmental area dopamine neurons but is not rewarding in mice or baboons | journal = The Journal of Neuroscience | volume = 32 | issue = 15 | pages = 5310–20 | date = April 2012 | pmid = 22496576 | doi = 10.1523/JNEUROSCI.4697-11.2012 | pmc = 6622081 | doi-access = free }}</ref> and simultaneously does not inhibit REM sleep,{{citation needed}} this is a trait currently unique to Gaboxadol and some related [[GABAergic]]s such as [[pregabalin]]

{{citation needed}}, [[GHB]]{{citation needed}} or [[cinazepam]].{{citation needed}}

In high doses, Gaboxadol produces distinct [[deliriant]] effects but not in the manner of traditional [[deliriants]]. It can be categorized as a "GABAergic deliriant". It is said to have similar effects to muscimol and [[zolpidem]].

Line 114:

Line 115:

==External links==

*[https://en.wikipedia.org/wiki/Gaboxadol Gaboxadol (Wikipedia)]

*[https://isomerdesign.com/PiHKAL/explore.php?id=646 Gaboxadol (Isomer Design)]

==References==

[[Category:3-Hydroxyisoxazole]]

[[Category:Depressant]]

[[Category:GABAergic hallucinogens]]

[[Category:Deliriant]]

@@ Line 2: / Line 2: @@
 {{SummarySheet}}
-'''''Gaboxadol''''' is a [[depressant]] substance of the [[isoxazole]] class that produces [[sedative]], [[anxiolytic]], [[hypnotic]] and distinct [[hallucinogenic]] effects. It is chemically related to [[muscimol]], which is the primary alkaloid responsible for the [[psychoactive]] effects of [[amanita muscaria]]. It has been specifically developed alongside hundreds of other analogs to display more pronounced and selective therapeutic effects as well as a higher bioavailability than its parent compound muscimol.{{citation needed}}
+'''Gaboxadol''' (also knows as '''THIP''', '''OV101''' and '''LU-2-030''') is a [[depressant]] substance of the [[chemical class::3-hydroxyisoxazole]] class that produces [[sedative]], [[anxiolytic]], [[hypnotic]] and distinct [[hallucinogenic]] effects. It is chemically related to [[muscimol]], which is the primary alkaloid responsible for the [[psychoactive]] effects of [[amanita muscaria]]. It has been specifically developed alongside hundreds of other analogs to display more pronounced and selective therapeutic effects as well as a higher bioavailability than its parent compound muscimol.{{citation needed}}
 It was first synthesized in 1977 by the Danish chemist Povl Krogsgaard-Larsen. Since then it was subject to numerous medical evaluations for potential applications as an anxiolytic and hypnotic as well as treating conditions such as Alzheimer's disease among others. It's latest attempt at clinical trials was for the treatment of insomnia, although the trials have been cancelled.<ref>http://harpers.org/archive/2013/08/gaboxadol/</ref><ref>US Patent 4278676 - Heterocyclic compounds</ref>
-According to its pharmacological action, it is among a few hypnotic substances that do not negatively alter or suppress sleep and sleep architecture. It increases stage 4 deep sleep<ref>{{cite journal | vauthors = Vashchinkina E, Panhelainen A, Vekovischeva OY, Aitta-aho T, Ebert B, Ator NA, Korpi ER | title = GABA site agonist gaboxadol induces addiction-predicting persistent changes in ventral tegmental area dopamine neurons but is not rewarding in mice or baboons | journal = The Journal of Neuroscience | volume = 32 | issue = 15 | pages = 5310–20 | date = April 2012 | pmid = 22496576 | doi = 10.1523/JNEUROSCI.4697-11.2012 | pmc = 6622081 | doi-access = free }}</ref> and simultaneously does not inhibit REM sleep,{{citation needed}} this is a trait currently unique to Gaboxadol.
+According to its pharmacological action, it is among a few hypnotic substances that do not negatively alter or suppress sleep and sleep architecture. It increases stage 4 deep sleep<ref>{{cite journal | vauthors = Vashchinkina E, Panhelainen A, Vekovischeva OY, Aitta-aho T, Ebert B, Ator NA, Korpi ER | title = GABA site agonist gaboxadol induces addiction-predicting persistent changes in ventral tegmental area dopamine neurons but is not rewarding in mice or baboons | journal = The Journal of Neuroscience | volume = 32 | issue = 15 | pages = 5310–20 | date = April 2012 | pmid = 22496576 | doi = 10.1523/JNEUROSCI.4697-11.2012 | pmc = 6622081 | doi-access = free }}</ref> and simultaneously does not inhibit REM sleep,{{citation needed}} this is a trait currently unique to Gaboxadol and some related [[GABAergic]]s such as [[pregabalin]]
+{{citation needed}}, [[GHB]]{{citation needed}} or [[cinazepam]].{{citation needed}}
 In high doses, Gaboxadol produces distinct [[deliriant]] effects but not in the manner of traditional [[deliriants]]. It can be categorized as a "GABAergic deliriant". It is said to have similar effects to muscimol and [[zolpidem]].
@@ Line 114: / Line 115: @@
 ==External links==
 *[https://en.wikipedia.org/wiki/Gaboxadol Gaboxadol (Wikipedia)]
+*[https://isomerdesign.com/PiHKAL/explore.php?id=646 Gaboxadol (Isomer Design)]
 ==References==
 <references/>
+[[Category:3-Hydroxyisoxazole]]
 [[Category:Depressant]]
 [[Category:GABAergic hallucinogens]]
 [[Category:Deliriant]]